Active Biotech Year End Report 2022
FOURTH QUARTER IN BRIEF
- Active Biotech further strengthened the patent protection for laquinimod in eye disorders with a granted patent in US (Oct 24)
- Preclinical data with tasquinimod in MDS presented at ASH 2022 (Dec 13)
- Phase I Multiple dose study of laquinimod recruited final patient
OTHER SIGNIFICANT EVENTS JAN – DEC 2022
- Active Biotech appointed Erik Vahtola as Chief Medical Officer (Jan 4)
- Active Biotech announced first patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 7)
- Active Biotech entered into a global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis (Feb 9)
- Active Biotech strengthened the patent protection for laquinimod in eye disorders (Apr 26)
- FDA granted Orphan Drug Designation for tasquinimod in myelofibrosis (May 18)
- Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study started enrolling into the second stage (Jun 1)
- Active Biotech announced final outcome of the Company’s rights issue (Sep 7)
EVENTS AFTER THE END OF THE PERIOD
- Preclinical data with tasquinimod published in Journal of Immunotherapy for Cancer
- Active Biotech confirms positive safety profile of laquinimod eye drops (Jan 30, 2023)
FINANCIAL SUMMARY
| SEK M | Oct-Dec | Jan-Dec | ||
| 2022 2021 | 2022 2021 | |||
| Net sales | – | – | – | – |
| Operating profit/loss | -15.2 | -16.1 | -57.9 | -49.8 |
| Profit/loss after tax | -15.0 | -16.2 | -58.4 | -49.8 |
| Earnings per share (SEK) | -0.06 | -0.07 | -0.25 | -0.23 |
| Cash and cash equivalents (at close of period) | 41.8 | 53.1 | ||
The report is also available at www.activebiotech.com